types of glp-1 receptor agonists for individualized treatment type 2 diabetes mellitus Frontiers | Clinical perspectives on
Description
This study investigated the potential association between GLP-1RAs and SSIBs by exploring the FDA Adverse Event Reporting System (FAERS) database
The GLP-1 market is expected to hit $200 billion by 2031, according to a new study.
Both cohorts were followed until 29 March 2021
The science, promise and clinical development of GLP-1 and GIP receptor agonists in obesity
After their success in the obesity field, GLP-1 agonists are gaining interest in addiction treatment
